Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Molecular Testing for NSCLC in 2019

July 19th 2019

Dr. Gainor on Subgroup Analyses From the PACIFIC Trial in NSCLC

July 17th 2019

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, and assistant professor of medicine, Harvard Medical School, discusses subgroup analyses from the phase III PACIFIC trial in unresectable stage III non–small cell lung cancer (NSCLC).

Selective Inhibitors of Rare Mutations Show Encouraging Activity in NSCLC

July 16th 2019

Jessica Jiyeong Lin, MD, discusses rare oncogenic drivers and elaborates on the updated efficacy analyses that were presented at the 2019 ASCO Annual Meeting.

Weighing Treatment Strategies in ALK+ NSCLC

July 15th 2019

Alice T. Shaw, MD, PhD, provides an overlay of current treatment strategies in ALK-positive NSCLC and highlights research on the horizon.

Dr. Girard on Rationale for PACIFIC-R Study for NSCLC

July 13th 2019

Nicolas Girard, MD, discusses the rationale for the PACIFIC-R study, which is examining patients with unresectable stage III non–small cell lung cancer who received durvalumab.

Emerging Trends and Combination Therapies for ALK+ NSCLC

July 12th 2019

Sequencing Strategies for ALK-Targeted Therapy

July 12th 2019

Available Choices in ALK+ Therapy and Rationale for Selection

July 12th 2019

ALTA II: Brigatinib in Crizotinib-Resistant ALK+ NSCLC

July 12th 2019

Second-Line Treatment for ALK-Positive NSCLC

July 12th 2019

Resistance to ALK TKIs

July 12th 2019

Progression in ALK+ NSCLC After Frontline Therapy

July 12th 2019

ALTA-1L: Brigatinib Versus Crizotinib for ALK+ NSCLC

July 12th 2019

Factors to Consider in Choosing ALK TKIs in Frontline Setting

July 12th 2019

ALK-Positive NSCLC: ASCEND-4 Trial

July 12th 2019

ALK-Positive NSCLC: ALEX Trial

July 12th 2019

Targeted TKIs Used for Treatment of ALK-Positive NSCLC

July 12th 2019

Efforts Continue to Increase Lung Cancer Screening

July 11th 2019

Inga T. Lennes, MD, MBA, MPH, discusses the recommended screening protocol for patients at risk for lung cancer, maintaining patients post-screening, and how physicians can best assist this patient population.

Studies Continue to Evaluate Potential With Pemetrexed in NSCLC

July 10th 2019

Mary Jo J. Fidler, MD, discusses intriguing data with pemetrexed in patients with nonsquamous non–small cell lung cancer.

Dr. Malhotra on Pembrolizumab During Concurrent Chemoradiation in NSCLC

July 9th 2019

Jyoti Malhotra, MD, MPH, discusses a phase I multicenter trial of PD-1 blockade with pembrolizumab with concurrent chemoradiation in patients with locally advanced, unresectable non–small cell lung cancer.